P7 antigen expression in human breast cancer

Xiaowei Yang, Susan Groshen, Silvia C. Formenti, Nancy E. Davidson, Michael F. Press

Research output: Contribution to journalArticle

Abstract

Purpose: Evaluate p7 expression in human breast cancer and determine whether chemotherapy and radiation therapy effect a change in p7 expression. Experimental Design: Using a p7-specific monoclonal antibody with immunohistochemistry and Western immunoblot analyses to assess p7 expression in archival, frozen breast cancer specimens both before and after therapy. Results: A novel 7 kDa protein (p7), originally identified in multidrug-resistant ovarian and breast cancer cell lines, was found to be expressed in 21 of 64 (32%) primary, unselected human breast cancer specimens by immunohistochemistry with the use of a p7-specific monoclonal antibody, 1D7. P7 was observed in malignant cells but not in other types of cells in the breast tissue. Western blot analysis confirmed the 7 kDa polypeptide in p7-positive breast carcinomas identified by immunohistochemistry. P7 expression was significantly associated with breast cancers having distant metastasis and/or local recurrence (P = 0.027, Fisher's exact test). In addition, p7 expression was significantly increased in post-treatment breast cancer biopsy specimens compared with pretreatment breast cancer biopsy specimens in patients with locally advanced breast cancer after 5-fluorouracil chemotherapy and radiation therapy [2 of 15 (13%) pretreatment breast cancers compared with 8 of 15 (53%) post-treatment breast cancers; P = 0.016, McNemar's test]. Conclusions: These findings demonstrate that expression of p7 is associated with malignant tumor cells in primary breast cancers, especially those showing recurrent or metastatic disease. Its specific association with the malignant phenotype suggests it may have potential for novel target-based therapies. The markedly increased expression in patients with locally advanced disease after neoadjuvant therapy suggests a role for p7 in treatment outcome.

Original languageEnglish (US)
Pages (from-to)201-206
Number of pages6
JournalClinical Cancer Research
Volume9
Issue number1 I
StatePublished - Jan 1 2003

Fingerprint

Breast Neoplasms
Antigens
Immunohistochemistry
Radiotherapy
Western Blotting
Monoclonal Antibodies
Biopsy
Drug Therapy
Neoadjuvant Therapy
Radiation Effects
Therapeutics
Fluorouracil
Ovarian Neoplasms
Breast
Research Design
Neoplasm Metastasis
Phenotype
Recurrence
Cell Line
Peptides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yang, X., Groshen, S., Formenti, S. C., Davidson, N. E., & Press, M. F. (2003). P7 antigen expression in human breast cancer. Clinical Cancer Research, 9(1 I), 201-206.

P7 antigen expression in human breast cancer. / Yang, Xiaowei; Groshen, Susan; Formenti, Silvia C.; Davidson, Nancy E.; Press, Michael F.

In: Clinical Cancer Research, Vol. 9, No. 1 I, 01.01.2003, p. 201-206.

Research output: Contribution to journalArticle

Yang, X, Groshen, S, Formenti, SC, Davidson, NE & Press, MF 2003, 'P7 antigen expression in human breast cancer', Clinical Cancer Research, vol. 9, no. 1 I, pp. 201-206.
Yang X, Groshen S, Formenti SC, Davidson NE, Press MF. P7 antigen expression in human breast cancer. Clinical Cancer Research. 2003 Jan 1;9(1 I):201-206.
Yang, Xiaowei ; Groshen, Susan ; Formenti, Silvia C. ; Davidson, Nancy E. ; Press, Michael F. / P7 antigen expression in human breast cancer. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 1 I. pp. 201-206.
@article{7947b21fe6bb48a9922a10f3f58094c1,
title = "P7 antigen expression in human breast cancer",
abstract = "Purpose: Evaluate p7 expression in human breast cancer and determine whether chemotherapy and radiation therapy effect a change in p7 expression. Experimental Design: Using a p7-specific monoclonal antibody with immunohistochemistry and Western immunoblot analyses to assess p7 expression in archival, frozen breast cancer specimens both before and after therapy. Results: A novel 7 kDa protein (p7), originally identified in multidrug-resistant ovarian and breast cancer cell lines, was found to be expressed in 21 of 64 (32{\%}) primary, unselected human breast cancer specimens by immunohistochemistry with the use of a p7-specific monoclonal antibody, 1D7. P7 was observed in malignant cells but not in other types of cells in the breast tissue. Western blot analysis confirmed the 7 kDa polypeptide in p7-positive breast carcinomas identified by immunohistochemistry. P7 expression was significantly associated with breast cancers having distant metastasis and/or local recurrence (P = 0.027, Fisher's exact test). In addition, p7 expression was significantly increased in post-treatment breast cancer biopsy specimens compared with pretreatment breast cancer biopsy specimens in patients with locally advanced breast cancer after 5-fluorouracil chemotherapy and radiation therapy [2 of 15 (13{\%}) pretreatment breast cancers compared with 8 of 15 (53{\%}) post-treatment breast cancers; P = 0.016, McNemar's test]. Conclusions: These findings demonstrate that expression of p7 is associated with malignant tumor cells in primary breast cancers, especially those showing recurrent or metastatic disease. Its specific association with the malignant phenotype suggests it may have potential for novel target-based therapies. The markedly increased expression in patients with locally advanced disease after neoadjuvant therapy suggests a role for p7 in treatment outcome.",
author = "Xiaowei Yang and Susan Groshen and Formenti, {Silvia C.} and Davidson, {Nancy E.} and Press, {Michael F.}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "9",
pages = "201--206",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1 I",

}

TY - JOUR

T1 - P7 antigen expression in human breast cancer

AU - Yang, Xiaowei

AU - Groshen, Susan

AU - Formenti, Silvia C.

AU - Davidson, Nancy E.

AU - Press, Michael F.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Purpose: Evaluate p7 expression in human breast cancer and determine whether chemotherapy and radiation therapy effect a change in p7 expression. Experimental Design: Using a p7-specific monoclonal antibody with immunohistochemistry and Western immunoblot analyses to assess p7 expression in archival, frozen breast cancer specimens both before and after therapy. Results: A novel 7 kDa protein (p7), originally identified in multidrug-resistant ovarian and breast cancer cell lines, was found to be expressed in 21 of 64 (32%) primary, unselected human breast cancer specimens by immunohistochemistry with the use of a p7-specific monoclonal antibody, 1D7. P7 was observed in malignant cells but not in other types of cells in the breast tissue. Western blot analysis confirmed the 7 kDa polypeptide in p7-positive breast carcinomas identified by immunohistochemistry. P7 expression was significantly associated with breast cancers having distant metastasis and/or local recurrence (P = 0.027, Fisher's exact test). In addition, p7 expression was significantly increased in post-treatment breast cancer biopsy specimens compared with pretreatment breast cancer biopsy specimens in patients with locally advanced breast cancer after 5-fluorouracil chemotherapy and radiation therapy [2 of 15 (13%) pretreatment breast cancers compared with 8 of 15 (53%) post-treatment breast cancers; P = 0.016, McNemar's test]. Conclusions: These findings demonstrate that expression of p7 is associated with malignant tumor cells in primary breast cancers, especially those showing recurrent or metastatic disease. Its specific association with the malignant phenotype suggests it may have potential for novel target-based therapies. The markedly increased expression in patients with locally advanced disease after neoadjuvant therapy suggests a role for p7 in treatment outcome.

AB - Purpose: Evaluate p7 expression in human breast cancer and determine whether chemotherapy and radiation therapy effect a change in p7 expression. Experimental Design: Using a p7-specific monoclonal antibody with immunohistochemistry and Western immunoblot analyses to assess p7 expression in archival, frozen breast cancer specimens both before and after therapy. Results: A novel 7 kDa protein (p7), originally identified in multidrug-resistant ovarian and breast cancer cell lines, was found to be expressed in 21 of 64 (32%) primary, unselected human breast cancer specimens by immunohistochemistry with the use of a p7-specific monoclonal antibody, 1D7. P7 was observed in malignant cells but not in other types of cells in the breast tissue. Western blot analysis confirmed the 7 kDa polypeptide in p7-positive breast carcinomas identified by immunohistochemistry. P7 expression was significantly associated with breast cancers having distant metastasis and/or local recurrence (P = 0.027, Fisher's exact test). In addition, p7 expression was significantly increased in post-treatment breast cancer biopsy specimens compared with pretreatment breast cancer biopsy specimens in patients with locally advanced breast cancer after 5-fluorouracil chemotherapy and radiation therapy [2 of 15 (13%) pretreatment breast cancers compared with 8 of 15 (53%) post-treatment breast cancers; P = 0.016, McNemar's test]. Conclusions: These findings demonstrate that expression of p7 is associated with malignant tumor cells in primary breast cancers, especially those showing recurrent or metastatic disease. Its specific association with the malignant phenotype suggests it may have potential for novel target-based therapies. The markedly increased expression in patients with locally advanced disease after neoadjuvant therapy suggests a role for p7 in treatment outcome.

UR - http://www.scopus.com/inward/record.url?scp=12244280809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244280809&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 201

EP - 206

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1 I

ER -